FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (nmus rehab) as pain management therapies.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Musculoskeletal · Chronic Pain
- Sub-indication
- Nmus Rehab
Related signal: Study on Music Therapy's Effects in Chronic Neck Pain Rehabilitation